These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 30354145)

  • 1. Polymer-Temozolomide Conjugates as Therapeutics for Treating Glioblastoma.
    Ward SM; Skinner M; Saha B; Emrick T
    Mol Pharm; 2018 Nov; 15(11):5263-5276. PubMed ID: 30354145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Versatile Synthesis of Polymer-Temozolomide Conjugates.
    Skinner M; Ward SM; Emrick T
    ACS Macro Lett; 2017 Mar; 6(3):215-218. PubMed ID: 35650916
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polymeric phosphorylcholine-camptothecin conjugates prepared by controlled free radical polymerization and click chemistry.
    Chen X; McRae S; Parelkar S; Emrick T
    Bioconjug Chem; 2009 Dec; 20(12):2331-41. PubMed ID: 19899739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and Validation of a Targeted Treatment for Brain Tumors Using a Multi-Drug Loaded, Relapse-Resistant Polymeric Theranostic.
    Chu W; Houston ZH; Fletcher NL; Huda P; Ahamed M; Lim TX; Day BW; Pinkham M; Thurecht KJ
    Biomacromolecules; 2023 Jun; 24(6):2674-2690. PubMed ID: 37143361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Temozolomide-loaded photopolymerizable PEG-DMA-based hydrogel for the treatment of glioblastoma.
    Fourniols T; Randolph LD; Staub A; Vanvarenberg K; Leprince JG; Préat V; des Rieux A; Danhier F
    J Control Release; 2015 Jul; 210():95-104. PubMed ID: 25982679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual-targeting immunoliposomes using angiopep-2 and CD133 antibody for glioblastoma stem cells.
    Kim JS; Shin DH; Kim JS
    J Control Release; 2018 Jan; 269():245-257. PubMed ID: 29162480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brain Targeting by Liposome-Biomolecular Corona Boosts Anticancer Efficacy of Temozolomide in Glioblastoma Cells.
    Arcella A; Palchetti S; Digiacomo L; Pozzi D; Capriotti AL; Frati L; Oliva MA; Tsaouli G; Rota R; Screpanti I; Mahmoudi M; Caracciolo G
    ACS Chem Neurosci; 2018 Dec; 9(12):3166-3174. PubMed ID: 30015470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biodegradable wafers releasing Temozolomide and Carmustine for the treatment of brain cancer.
    Shapira-Furman T; Serra R; Gorelick N; Doglioli M; Tagliaferri V; Cecia A; Peters M; Kumar A; Rottenberg Y; Langer R; Brem H; Tyler B; Domb AJ
    J Control Release; 2019 Feb; 295():93-101. PubMed ID: 30605703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Visible Light and Glutathione Dually Responsive Delivery of a Polymer-Conjugated Temozolomide Intermediate for Glioblastoma Chemotherapy.
    Du K; Xia Q; Sun J; Feng F
    ACS Appl Mater Interfaces; 2021 Dec; 13(47):55851-55861. PubMed ID: 34788006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improving temozolomide biopharmaceutical properties in glioblastoma multiforme (GBM) treatment using GBM-targeting nanocarriers.
    Delello Di Filippo L; Hofstätter Azambuja J; Paes Dutra JA; Tavares Luiz M; Lobato Duarte J; Nicoleti LR; Olalla Saad ST; Chorilli M
    Eur J Pharm Biopharm; 2021 Nov; 168():76-89. PubMed ID: 34461214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PolyMPC-doxorubicin prodrugs.
    Chen X; Parelkar SS; Henchey E; Schneider S; Emrick T
    Bioconjug Chem; 2012 Sep; 23(9):1753-63. PubMed ID: 22881479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Encapsulation of Temozolomide in a Calixarene Nanocapsule Improves Its Stability and Enhances Its Therapeutic Efficacy against Glioblastoma.
    Renziehausen A; Tsiailanis AD; Perryman R; Stylos EK; Chatzigiannis C; O'Neill K; Crook T; Tzakos AG; Syed N
    Mol Cancer Ther; 2019 Sep; 18(9):1497-1505. PubMed ID: 31213505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determination of an optimal dosing schedule for combining Irinophore C™ and temozolomide in an orthotopic model of glioblastoma.
    Verreault M; Wehbe M; Strutt D; Masin D; Anantha M; Walker D; Chu F; Backstrom I; Kalra J; Waterhouse D; Yapp DT; Bally MB
    J Control Release; 2015 Dec; 220(Pt A):348-357. PubMed ID: 26528901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Temozolomide-Doxorubicin Conjugate as a Double Intercalating Agent and Delivery by Apoferritin for Glioblastoma Chemotherapy.
    Du K; Xia Q; Heng H; Feng F
    ACS Appl Mater Interfaces; 2020 Aug; 12(31):34599-34609. PubMed ID: 32648735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lumefantrine, an antimalarial drug, reverses radiation and temozolomide resistance in glioblastoma.
    Rajesh Y; Biswas A; Kumar U; Banerjee I; Das S; Maji S; Das SK; Emdad L; Cavenee WK; Mandal M; Fisher PB
    Proc Natl Acad Sci U S A; 2020 Jun; 117(22):12324-12331. PubMed ID: 32409605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discordant in vitro and in vivo chemopotentiating effects of the PARP inhibitor veliparib in temozolomide-sensitive versus -resistant glioblastoma multiforme xenografts.
    Gupta SK; Mladek AC; Carlson BL; Boakye-Agyeman F; Bakken KK; Kizilbash SH; Schroeder MA; Reid J; Sarkaria JN
    Clin Cancer Res; 2014 Jul; 20(14):3730-41. PubMed ID: 24838527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polymeric and small molecule-conjugates of temozolomide as improved therapeutic agents for glioblastoma multiforme.
    Jatyan R; Singh P; Sahel DK; Karthik YG; Mittal A; Chitkara D
    J Control Release; 2022 Oct; 350():494-513. PubMed ID: 35985493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced Caspase-Mediated Abrogation of Autophagy by Temozolomide-Loaded and Panitumumab-Conjugated Poly(lactic-
    Banstola A; Duwa R; Emami F; Jeong JH; Yook S
    Mol Pharm; 2020 Nov; 17(11):4386-4400. PubMed ID: 33079558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel RGD containing, temozolomide-loading nanostructured lipid carriers for glioblastoma multiforme chemotherapy.
    Song S; Mao G; Du J; Zhu X
    Drug Deliv; 2016 May; 23(4):1404-8. PubMed ID: 26203687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PARP‑1 inhibition sensitizes temozolomide‑treated glioblastoma cell lines and decreases drug resistance independent of MGMT activity and PTEN proficiency.
    Montaldi AP; Lima SCG; Godoy PRDV; Xavier DJ; Sakamoto-Hojo ET
    Oncol Rep; 2020 Nov; 44(5):2275-2287. PubMed ID: 32901889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.